Title:
MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED beta2-MICROGLOBULIN
Document Type and Number:
WIPO Patent Application WO2005099361
Kind Code:
A3
Abstract:
The present invention is directed to a novel targeted vaccine delivery system, comprising one or more peptide-MHC Class I complexes linked through the beta2-microglobulin molecule to an antibody which is specific for a cell surface marker. The complexes of the invention contain a beta2-microglobulin that has been modified to have greater affinity to the alpha chain of MHC Class I than native beta2-microglobulin. Alternatively, the complexes of the invention contain beta2-microglobulin fused or linked to the antigenic peptide. The complexes of the invention are useful for treating and/or preventing cancer, infectious diseases, autoimmune diseases, and/or allergies.
Inventors:
ZAUDERER MAURICE (US)
Application Number:
PCT/US2004/022055
Publication Date:
December 15, 2005
Filing Date:
July 09, 2004
Export Citation:
Assignee:
VACCINEX INC (US)
ZAUDERER MAURICE (US)
ZAUDERER MAURICE (US)
International Classes:
A61K47/48; C07K14/74; C07K16/00; C07K16/28; C07K16/46; (IPC1-7): C07K16/00; C07K16/28
Domestic Patent References:
| WO1999064597A1 | 1999-12-16 |
Foreign References:
| US20040096429A1 | 2004-05-20 | |||
| US20040091488A1 | 2004-05-13 | |||
| US20020123108A1 | 2002-09-05 |
Other References:
ZEMON H. ET AL.: "An Artificial for adoptive immunotherapy.", TRENDS IN BIOTECHNOLOGY., vol. 21, no. 10, October 2003 (2003-10-01), pages 418 - 420, XP004458103
TIMMERMAN ET AL.: "Dendritic cell vaccines for cancer immunotherapy.", ANNU. REV. MED., vol. 50, 1999, pages 507 - 529, XP001005422
TIMMERMAN ET AL.: "Dendritic cell vaccines for cancer immunotherapy.", ANNU. REV. MED., vol. 50, 1999, pages 507 - 529, XP001005422
Download PDF: